New Drugs

Brand/Generic Company Description
Alhemo
concizumab
Novo Nordisk Canada

A new anti-tissue factor pathway inhibitor antibody for hemophilia B.

Beyfortus
nirsevimab
AstraZeneca/Sanofi

A new long-acting antibody for the prevention of respiratory syncytial virus (RSV) in neonates, infants, and children up to 24 months of age.

Carvykti
ciltacabtagene autoleucel
Janssen

A new B-cell maturation antigen (BCMA)-directed T-cell IV immunotherapy for adults with multiple myeloma.

Columvi
glofitamab
Hoffmann-La Roche

A new CD20/CD-3 binding monoclonal antibody for B-cell lymphoma.

Kengrexal
cangrelor
Methapharm

A new IV direct P2Y12 platelet receptor inhibitor for patients with coronary artery disease undergoing percutaneous coronary intervention (PCI).

Quviviq
daridorexant
Idorsia/Innomar Strategies

A new oral dual orexin receptor antagonist for insomnia in adults.

Spevigo
spesolimab
Boehringer Ingelheim Canada

A new interleukin-36 inhibitor for generalized pustular psoriasis.

Vegzelma
bevacizumab
Celltrion

A biosimilar to Avastin.

Verquvo
vericiguat
Bayer

A new oral soluble guanylate cyclase (sGC) stimulator for symptomatic heart failure with reduced ejection fraction (HFrEF) in adults.

Brand/Generic Company Description
Calquence
acalabrutinib maleate
AstraZeneca

New tablet dosage form that does not interact with gastric acid reducing agents

Ferriprox MR
deferiprone
Chiesi Canada

New extended-release tablet that allows for twice daily dosing.

Zoryve
roflumilast
Arcutis Biotherapeutics

New topical cream for plaque psoriasis.

Brand/Generic Company Description